Literature DB >> 23269559

Lacosamide improves outcome in a murine model of traumatic brain injury.

Bo Wang1, Hana Dawson, Haichen Wang, Dawn Kernagis, Brad J Kolls, Lucy Yao, Daniel T Laskowitz.   

Abstract

BACKGROUND: Use of antiepileptic drugs (AED's) is common in the neurocritical care setting. However, there remains a great deal of controversy regarding the optimal agent. Studies associating the prophylactic use of AED's with poor outcomes are heavily biased by the prevalent use of phenytoin, an agent highly associated with deleterious effects. In the current study, we evaluate lacosamide for neuroprotective properties in a murine model of closed head injury.
METHODS: Mice were subjected to moderate closed head injury using a pneumatic impactor, and then treated with either low-dose (6 mg/kg) or high-dose (30 mg/kg) lacosamide or vehicle at 30 min post-injury, and twice daily for 3 days after injury. Motor and cognitive functional assessments were performed following injury using rotarod and Morris Water Maze, respectively. Neuronal injury and microglial activation were measured by flourojade-B, NeuN, and F4/80 staining at 1 and 7 days post-injury. Timm's staining was also performed to assess lacosamide effects on mossy fiber axonal sprouting. To evaluate possible mechanisms of lacosamide effects on the inflammatory response to injury, an RNA expression array was used to evaluate for alterations in differential gene expression patterns in injured mice following lacosamide or vehicle treatments.
RESULTS: High-dose lacosamide was associated with improved functional outcome on both the rotarod and Morris Water Maze. High-dose lacosamide was also associated with a reduction of neuronal injury at 24 h post-injury. However, the reduction in neuronal loss observed early did not result in greater neuronal density at 31 days post-injury based on unbiased stereology of NeuN staining. High-dose lacosamide was also associated with a significant reduction in microglial activation at 7 days post-injury. The therapeutic effects of lacosamide are associated with a delay in injury-related changes in RNA expression of a subset of inflammatory mediator genes typically seen at 24 h post-injury.
CONCLUSIONS: Administration of lacosamide improves functional performance, and reduces histological evidence of acute neuronal injury and neuroinflammation in a murine model of closed head injury. Lacosamide effects appear to be mediated via a reduction or delay in the acute inflammatory response to injury. Prior clinical and animal studies have found antiepileptic treatment following injury to be detrimental, though these studies are biased by the common use of older medications such as phenytoin. Our current results as well as prior work on levetiracetam suggest the newer AED's may be beneficial in the setting of acute brain injury.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23269559     DOI: 10.1007/s12028-012-9808-8

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  50 in total

1.  Extracellular superoxide dismutase overexpression improves behavioral outcome from closed head injury in the mouse.

Authors:  J A Pineda; M Aono; H Sheng; J Lynch; J C Wellons; D T Laskowitz; R D Pearlstein; R Bowler; J Crapo; D S Warner
Journal:  J Neurotrauma       Date:  2001-06       Impact factor: 5.269

2.  Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis.

Authors:  Susan L Bratton; Randall M Chestnut; Jamshid Ghajar; Flora F McConnell Hammond; Odette A Harris; Roger Hartl; Geoffrey T Manley; Andrew Nemecek; David W Newell; Guy Rosenthal; Joost Schouten; Lori Shutter; Shelly D Timmons; Jamie S Ullman; Walter Videtta; Jack E Wilberger; David W Wright
Journal:  J Neurotrauma       Date:  2007       Impact factor: 5.269

3.  Traumatic brain injury exacerbates neurodegenerative pathology: improvement with an apolipoprotein E-based therapeutic.

Authors:  Daniel T Laskowitz; Pingping Song; Haichen Wang; Brian Mace; Patrick M Sullivan; Michael P Vitek; Hana N Dawson
Journal:  J Neurotrauma       Date:  2010-11-02       Impact factor: 5.269

4.  Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage.

Authors:  Andrew M Naidech; Kurt T Kreiter; Nazli Janjua; Noeleen Ostapkovich; Augusto Parra; Christopher Commichau; E Sander Connolly; Stephan A Mayer; Brian-Fred M Fitzsimmons
Journal:  Stroke       Date:  2005-01-20       Impact factor: 7.914

5.  Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema.

Authors:  John R Lynch; Jose A Pineda; Duncan Morgan; Lin Zhang; David S Warner; Helen Benveniste; Daniel T Laskowitz
Journal:  Ann Neurol       Date:  2002-01       Impact factor: 10.422

6.  Traumatic brain injury (TBI) 10-20 years later: a comprehensive outcome study of psychiatric symptomatology, cognitive abilities and psychosocial functioning.

Authors:  D Hoofien; A Gilboa; E Vakil; P J Donovick
Journal:  Brain Inj       Date:  2001-03       Impact factor: 2.311

Review 7.  Adverse cognitive effects of phenytoin in severe brain injury: a case report.

Authors:  Colin Pinder; Carolyn Young
Journal:  Brain Inj       Date:  2011       Impact factor: 2.311

8.  Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors.

Authors:  Akira Iwata; Peter K Stys; John A Wolf; Xiao-Han Chen; Andrew G Taylor; David F Meaney; Douglas H Smith
Journal:  J Neurosci       Date:  2004-05-12       Impact factor: 6.167

9.  Prescribing of potentially harmful drugs to patients admitted to hospital after head injury.

Authors:  L B Goldstein
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-06       Impact factor: 10.154

Review 10.  Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury: report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  Bernard S Chang; Daniel H Lowenstein
Journal:  Neurology       Date:  2003-01-14       Impact factor: 9.910

View more
  7 in total

Review 1.  Antiseizure medications in critical care: an update.

Authors:  Baxter Allen; Paul M Vespa
Journal:  Curr Opin Crit Care       Date:  2019-04       Impact factor: 3.687

Review 2.  Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide.

Authors:  Sarah M Wilson; Rajesh Khanna
Journal:  Mol Neurobiol       Date:  2014-06-20       Impact factor: 5.590

Review 3.  Novel Therapeutics for Neonatal Seizures.

Authors:  Julie M Ziobro; Krista Eschbach; Renée A Shellhaas
Journal:  Neurotherapeutics       Date:  2021-08-12       Impact factor: 6.088

4.  Neuroprotective Effect of Lacosamide on Hypoxic-Ischemic Brain Injury in Neonatal Rats.

Authors:  Gun Ha Kim; Jung Hye Byeon; Baik Lin Eun
Journal:  J Clin Neurol       Date:  2017-03-06       Impact factor: 3.077

5.  Novel antiepileptic drug lacosamide exerts neuroprotective effects by decreasing glial activation in the hippocampus of a gerbil model of ischemic stroke.

Authors:  Ji Yun Ahn; Bing Chun Yan; Joon Ha Park; Ji Hyeon Ahn; Dae Hwan Lee; In Hye Kim; Jeong-Hwi Cho; Bai Hui Chen; Jae-Chul Lee; Young Shin Cho; Myoung Chul Shin; Jun Hwi Cho; Seongkweon Hong; Moo-Ho Won; Sung Koo Kim
Journal:  Exp Ther Med       Date:  2015-10-13       Impact factor: 2.447

6.  Modulation of CRMP2 via (S)-Lacosamide shows therapeutic promise but is ultimately ineffective in a mouse model of CLN6-Batten disease.

Authors:  Katherine A White; Jacob T Cain; Helen Magee; Seul Ki Yeon; Ki Duk Park; Rajesh Khanna; Jill M Weimer
Journal:  Health Psychol Behav Med       Date:  2019-04-08

Review 7.  Microglia: A Potential Drug Target for Traumatic Axonal Injury.

Authors:  Xin Huang; Wendong You; Yuanrun Zhu; Kangli Xu; Xiaofeng Yang; Liang Wen
Journal:  Neural Plast       Date:  2021-05-20       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.